Latest / The Health Care Preview / House Gone, Senate Lingers
Transcript
- speaker-0: Hello and welcome to the Healthcare Preview, a weekly podcast from CoZund O'Connor Public Strategies, where we break down what's happening in health policy in Washington, D.C. I'm your host, Matty News, and I'm here today with my colleagues Debbie Curtis and Rodney Whitlock. How are you guys doing tonight? speaker-2: Well, first of all, it's Rodney's birthday. So let's all wish him happy birthday. I'm gonna be extra nice on this podcast. ⁓ speaker-1: No, you're not, but that's okay. And I appreciate it. Happy birthday. The greetings. Went out for a long bike ride this weekend, which allows me to to make this statement. You never get too old to bike. It's when you stop biking that you get old. So I'm gonna fight that a bit. speaker-2: And Ravi, how long was that bike ride just for curious people? speaker-1: Listen, old men always you know keep their stats. It's ⁓ I did a hundred and five. So I was you know, it was a lot of suffering, but I'm happy I did it while I still can. Thank you. speaker-2: Impressive. speaker-0: Very. And everyone celebrates their birthdays in different ways. So happy birthday, Rodney. And your birthday gift this week is also that the House is out of town. They left last Wednesday, but the Senate is still here. So what are they focused on this week? speaker-2: So the main focus for the Senate this week is going to try to from a healthcare perspective. Their main focus on the floor will be other issues. But in committee, it's going to be continued moving on nominations. And so the health committee will vote on Thursday on several of the health nominations. And then they are going to have a hearing with the new person to run FDA, the new nomination to run FDA that is. a hearing. That is not something we expect Congress to act on before the midterms, but we do anticipate that if they can be efficient with their time, there will be a package of nominations like we voted on that would include a number of high profile health people like Chris Klant to be the deputy secretary and Mary Lazar to run ACL. And there are some other people on that list as well. speaker-1: Yeah. Yeah, the Senate is certainly moving a direction that suggests they are going to get some nominations done before they leave town, but it's important to remember their calendar said they were always going to be in next week. And so while the House looked at things and said, I don't know why we're here. We should leave. The Senate may s stick to their schedule unless they're incredibly efficient this week. speaker-0: What else are we on the lookout for then? Is there anything at the administration? speaker-1: Well, that's a really really good question to put out there as we think about it, which is it's not as though the administration is sitting around when Congress is here going, Well, wait a second, Congress is here. No, they're always acting, but it is a little bit more of a vacuum when Congress isn't in town. House gone, Senate could be gone, you know, late this week, next week. And so then we will sort of look for the the administration right before an election. Are there things that they might suddenly bring up that we would keep an eye on? speaker-2: Yeah. And to that front, we certainly continue to wait for the fraud and abuse rule that we're expecting, the crush rule, which earlier this year the administration asked for input from people from stakeholders, from everyone around the country to get input on what they could more they could be doing on fraud. And so we do anticipate that one coming out sometime in the near future. We also have heard them speaking recently. They made some bake now. rebranded, unofficially rebranded IPRA plans, but they're HRAs that can be sold. And so they're rebranding those choice plans, which I have been saying for multiple years, they need a new name because IPRA just sounds like you have a dread disease. It doesn't sound like a product that's going to take care of your health. So we'll be watching for that one. And then of course there's been a lot of focus on What on the political oversight of grant making. And we know that the CR that Congress passed put a pause on the rule moving forward that broadly would do that. So that's on pause till December 11th. But the latest is that there may be a new rule coming or an executive order coming that would have both OMB and FDA involved in overseeing. very directly and very politically grant making from the National Institutes of Health. So we are watching that one and what may come out soon pretty closely. speaker-1: Yeah, that that last one is going to be fascinating because we're watching, and clearly this is not a news flash. This administration takes political actions. Okay, but here's another news flash. All administrations take political actions. But is the nature of the way this administration acts is it much more overt? Are they doing so in areas and spaces which warrant greater oversight? All of these things can be true, but it's going to be fascinating to watch. Is this effort going on with OMB trying to set up a more formalized process? Is that an effort to make the case that it's an appropriate step? Or does it end up just being, yeah, we don't trust you, we're not doing that, and they're gonna lose it in the CR? That's what we'll watch for. speaker-2: We are, and just one clarification, I misspoke. I said FDA. I meant the head of NIH. I did not mean the head of FDA because there is no head of the FDA, right? speaker-0: Very true. Well Debbie Rodney, thank you both for joining and thank you for tuning in to the Healthcare Preview. For more information on health policy and to subscribe to the Healthcare Preview, go to CoPublic Strategies.com. And until next time, I hope you have a great week.